Stay informed with the latest litigation news. Explore now
Nicotinamide Mononucleotide Derivatives And Use Thereof In The Treatment And Prevention Of A Red Blood Cell Disorder - EP4196127B1
EP4196127
- Application Number
- EP21839533A
- Filing Date
- Dec 17, 2021
- Status
- Granted And Under Opposition
- Dec 29, 2023
- Grant Date
- Jan 31, 2024
- External Links
- Slate, Register, Google Patents
- Similar Patents facing opposition
Bibliography
The patent EP4196127B1 was granted to Nuvamid on Jan 31, 2024 following the initial filing on Dec 17, 2021 under the application number EP21839533A . The current legal status of the patent is Granted And Under Opposition.
Patent Summary
Patent Family New
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Get instant alerts for new documents